Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2017

Jun 29, 2017

32254_dirs_2017-06-29_6811458c-0a2e-4716-ad01-4f504bedb1a5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2017-06-27

Reporting Person: Ross Leonard S (See Remarks)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-06-27 Restricted Stock Units $ A 20000 Acquired Common Stock (20000) Direct
2017-06-27 Stock Option (right to buy) $1.77 A 35000 Acquired 2027-06-27 Common Stock (35000) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F3: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018.